MML Investors Services LLC Has $4.72 Million Stock Holdings in argenx SE (NASDAQ:ARGX)

MML Investors Services LLC lifted its stake in shares of argenx SE (NASDAQ:ARGX - Free Report) by 16.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,699 shares of the company's stock after acquiring an additional 1,255 shares during the period. MML Investors Services LLC's holdings in argenx were worth $4,715,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Blue Trust Inc. lifted its position in argenx by 620.0% during the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company's stock worth $28,000 after buying an additional 62 shares in the last quarter. Point72 Hong Kong Ltd acquired a new stake in shares of argenx in the second quarter valued at about $76,000. Cromwell Holdings LLC raised its holdings in argenx by 73.3% during the third quarter. Cromwell Holdings LLC now owns 156 shares of the company's stock worth $85,000 after acquiring an additional 66 shares in the last quarter. GAMMA Investing LLC boosted its position in argenx by 47.5% during the third quarter. GAMMA Investing LLC now owns 174 shares of the company's stock valued at $94,000 after purchasing an additional 56 shares during the last quarter. Finally, Raymond James Trust N.A. bought a new position in argenx in the second quarter valued at approximately $201,000. Institutional investors own 60.32% of the company's stock.

argenx Stock Up 0.6 %

Shares of NASDAQ:ARGX traded up $3.81 during trading on Friday, reaching $607.21. 200,962 shares of the company traded hands, compared to its average volume of 307,889. The firm has a market capitalization of $36.66 billion, a PE ratio of -690.01 and a beta of 0.59. argenx SE has a 52 week low of $327.73 and a 52 week high of $630.00. The company's 50 day moving average is $581.03 and its two-hundred day moving average is $513.48.

argenx (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, topping the consensus estimate of $0.10 by $1.29. The business had revenue of $588.88 million during the quarter, compared to analysts' expectations of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. During the same quarter in the prior year, the business posted ($1.25) earnings per share. As a group, research analysts anticipate that argenx SE will post 2.2 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on ARGX shares. Scotiabank raised shares of argenx from a "sector perform" rating to a "sector outperform" rating and raised their target price for the company from $439.00 to $715.00 in a research note on Tuesday, November 5th. Wolfe Research raised shares of argenx from a "peer perform" rating to an "outperform" rating and set a $697.00 target price on the stock in a report on Tuesday, November 12th. Robert W. Baird cut argenx from an "outperform" rating to a "neutral" rating and lifted their price target for the stock from $515.00 to $650.00 in a report on Friday, November 1st. HC Wainwright reaffirmed a "buy" rating and issued a $617.00 price objective on shares of argenx in a research report on Wednesday, November 20th. Finally, Wells Fargo & Company boosted their target price on argenx from $547.00 to $639.00 and gave the stock an "overweight" rating in a report on Friday, November 1st. Three research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, argenx currently has an average rating of "Moderate Buy" and a consensus price target of $635.11.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.